Biocryst Pharmaceuticals (BCRX) Capital Expenditures (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Capital Expenditures came in at $608000.0 in Q1 2026, up 157.47% on a QoQ basis from -$1.1 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Capital Expenditures (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Capital Expenditures data on file, last reported at $608000.0 in Q1 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $608000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 617.45% YoY) and the FY2025 annual result came in at $608000.0, changed N/A from the prior year.
- Capital Expenditures rose to $608000.0 in Q1 2026, from -$1.1 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.1 million in Q2 2025 to a low of -$1.6 million in Q4 2023.
- A 5-year average of $160437.5 and a median of $325000.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 406.84% — and 2025, when it soared 554.89%.
- Tracing BCRX's Capital Expenditures over 5 years: stood at $526000.0 in 2022, then plunged by 406.84% to -$1.6 million in 2023, then surged by 72.18% to -$449000.0 in 2024, then slumped by 135.63% to -$1.1 million in 2025, then surged by 157.47% to $608000.0 in 2026.
- The last three Capital Expenditures figures came in at $608000.0 (Q1 2026), -$1.1 million (Q4 2025), and $597000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,000.00 |
| Jun 30, 2026 | 4,000.00 |
| Mar 31, 2026 | 608,000.00 |
| Mar 31, 2026 | 608,000.00 |
| Dec 31, 2025 | -1.06 Mn |
| Dec 31, 2025 | -1.06 Mn |
| Sep 30, 2025 | 597,000.00 |
| Sep 30, 2025 | 597,000.00 |
| Jun 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.07 Mn |
| Dec 31, 2024 | -449,000.00 |
| Dec 31, 2024 | -449,000.00 |
| Sep 30, 2024 | 449,000.00 |
| Sep 30, 2024 | 449,000.00 |
| Jun 30, 2024 | -235,000.00 |
| Jun 30, 2024 | -235,000.00 |
| Mar 31, 2024 | 235,000.00 |
| Mar 31, 2024 | 235,000.00 |
| Dec 31, 2023 | -1.61 Mn |
| Dec 31, 2023 | -1.61 Mn |